Classical neurotransmitters and neuropeptides involved in major depression: A review

International Journal of Neuroscience

Volumn 120, Issue 7, 2010, Pages 455-470

  Werner, Felix Martin ^a,b   Coveñas, Rafael ^b  

^a Hohere Berufsfachschule fur Altenpflege und Ergotherapie der Euro Schulen Poßneck ^*  (Germany)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Corticotropin releasing hormone; GABA; Glutamate; Noradrenaline; Receptor; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; ACETYLCHOLINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BUSPIRONE; CGP 25742; CGP 51176; CITALOPRAM; CORTICOTROPIN RELEASING FACTOR; DIZOCILPINE; DOPAMINE; FLUMAZENIL; FLUOXETINE; GALANIN; GLUTAMIC ACID; METABOTROPIC RECEPTOR 5; MIRTAZAPINE; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTRANSMITTER; NORADRENALIN; PROTIRELIN; REBOXETINE; RILUZOLE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

BRAIN REGION; DRUG EFFECT; DRUG MECHANISM; GABAERGIC TRANSMISSION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; INSOMNIA; MAJOR DEPRESSION; NERVOUS SYSTEM DEVELOPMENT; NERVOUSNESS; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANIMALS; BRAIN; BRAIN CHEMISTRY; DEPRESSIVE DISORDER, MAJOR; HUMANS; NEURAL INHIBITION; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS;

EID: 77954182731     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2010.483651     Document Type: Review

References (79)

1. Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007). Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology, 32(9), 1888-1902.
2. Berlanga, C., & Flores-Ramos, M. (2006). Different gender responses to serotonergic and noradrenergic antidepressant: A comparative study of the efficacy of citalopram and reboxetine. Journal of Affective Disorders, 95(1-3), 119-123.
3. Bielau, H., Steiner, J., Mawrin, C., Trubner, K., Brisch, R., Meyer-Lotz, G., et al. (2007). Dysregulation of GABAergic neurotransmission in mood disorders: A postmortem study. Annals of the New York Academy of Sciences, 1096, 157-169.
4. Blier, P., Gobbi, G., Haddjiri, N., Santarelli, L., Mathew, G., & Hen, R. (2004). Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: Relevance to the antidepressant/ anxiolytic response. Journal of Psychiatry & Neuroscience, 29(3), 208-218.
5. Bonaventure, P., Kelly, L., Aluisio, L., Shelton, J., Lord, B., Galici, R., et al. (2007). Selective blockade of 5-HT7 receptors enhances 5-HT neurotransmission, antidepressant-like behavior and REM sleep suppression induced by citalopram in rodents. The Journal of Pharmacology and Experimental Therapeutics, 321(2), 690-698.
6. Brundin, L., Björkqvist, M., Peterśen, A., & Traskman-Bendz, C. (2007). Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. European Neuropsychopharmacology, 17(9), 573-579.
7. Bschor, T., Lewitzka, U., Sasse, J., Adli, M., Koberle, U., & Bauer, M. (2003). Lithium augmentation in treatment-resistant depression: Clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry, 36(Suppl. 3), 230-234.
8. Cervilla, J. A., Molina, E., Rivera, M., Torres-Gonźalez, F., Belĺon, J. A., Moreno, B., et al. (2007). The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5-HTTLPR genotype: Evidence from the Spanish PREDICT Gen cohort. Molecular Psychiatry, 12(8), 748-755.
9. Chen, C., Wilcoxen, K. M., Huang, C. Q., Wie, Y. F., McCarthy, J. R., Webb, T. R., et al. (2004). Design of 2,5-dimethyl-3-(6-dimethyl-4- methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidini (NBI 30775/R 121919) and structure-activity relationships of a series of potent and orally active corticotropinreleasing factor receptor antagonists. Journal of Medicinal Chemistry, 47(19), 4787-4798.
10. Clayton, A. H. (2007). Extended-release bupropion: An antidepressant with a broad spectrum of therapeutic activity? ExpertOpinion on Pharmacotherapy, 8(4), 457-466.
11. Deuschle, M., Sander, P., Hernfer, I., Fiebich, B. L., Heuser, I., & Lieb, K. (2005). Substance P and cerebrospinal fluid of depressed patients: No effect of antidepressant treatment. Psychiatry Research, 136(1), 1-6.
12. de Winter, R. F., Ziman, F. G., von Houwelingen, J. C., Wolterbeek, R., & Goekoop, J. G. (2006). Anxious-retarded depression: Relation to two-year outcome of major depressive disorder. Journal of Affective Disorders, 90(1), 77-81.
13. Earnheart, J. C., Schweizer, C., Crestani, F., Iwasato, T., Itohara, S., Mohler,H., et al. (2007). GABAergic control of adult hippocampal neurogenesis in relation to behaviour indicative of trait anxiety and depression states. The Journal of Neuroscience, 27(14), 3845-3854.
14. Eser, D., Schüle, C., Baghai, T. C., Romero, E., Uzunov, D. P., & Rupprecht, R. (2006). Neuroactive steroids and affective disorders. Pharmacology, Biochemistry, and Behavior, 84(4), 656-666.
15. Foley, K. F., DeSanty, K. P., & Kast, R. E. (2006). Bupropion: Pharmacology and therapeutic applications. Expert Review of Neurotherapeutics, 6(9), 1249-1265.
16. Frieling, H., Hillemacher, T., Demling, J. H., Kornhuber, J., & Bleich, S. (2007). New options in the treatment of depression. Fortschritte der Neurologie-Psychiatrie, 75(11), 641-652.
17. Garćia-Colunga, J., V́azquez-Ǵomez, E., & Miledi, R. (2004). Combined actions of zinc and fluoxetine in nicotinic acetylcholine receptors. Pharmacogenomics, 4(6), 388-393.
18. Gendall, K. A., Joyce, P. R.,Mulder, R. I., & Luty, S. E. (2003). Thyroid indices and response to fluoxetine and nortriptyline in major depression. Journal of Psychopharmacology, 17(4), 431-437.
19. Geracioti, T. D., Jr., Carpenter, L. L., Owens, M. J., Baker, D. G., Eklator, N. N., Horn, P. S., et al. (2006). Elevated cerebrospianl fluid substance P concentrations in posttraumatic stress disorder andmajor depression. The American Journal of Psychiatry, 163(4), 637-643.
20. Gervasoni, N., Bertscho, G., Osieka, C., Pernet, G., Devis, R., Golaz, J., et al. (2004). Cortisol responses to combined dexamethasone/ CRH test in outpatients with a major depressive episode. Journal of Psychiatric Research, 38(6), 553-557.
21. Godin, O., Dufouil, C., Ritchie, K., Dartigues, J. F., Tzourio, C., Peres, K., et al. (2007). Depressive symptoms, major depressive episode and cognition in the elderly: The three-city study. Neuroepidemiology, 28(2), 101-108.
22. Goekoop, J. G., de Winter, R. P., de Rijk, R., Zwindermann, K. H., Frankhuijzen-Sierevogel, A., & Wiegant, W. M. (2006). Depression with above-normal plasma vasopressin validation by relations with family history of depression and mixed anxiety and retardation. Psychiatry Research, 141(2), 201-211.
23. Hasler, G., Van Der Veen, J. W., Tumonis, T.,Meyers, N., Shen, J., & Prevets, W. C. (2007). Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using positron magnetic resonance spectroscopy. Archives of General Psychiatry, 64(2), 193-200.
24. Hebb, A. L., Poulin, J. E., Roach, S. P., Zacharko, R. M., & Drolet, G. (2005). Cholecystokinin and endogenous opioid peptides: Interactive influence on pain, cognition, and emotion. Progress in Neuropsychopharmacology and Biological Psychiatry, 29(8), 1225-1238.
25. Held, K., Antonijivic, I., Murck, H., Kuenzel, H., & Steiger, A. (2006). Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls. Psychoneuroendocrinology, 31(1), 100-107.
26. Hemmeter, U., Hatzinger, M., Brand, S., & Holsboer-Trachsler, E. (2006). Effect of flumazenil-augmentation on microsleep and mood in depressed patients during partial sleep deprivation. Journal of Psychiatric Research, 41(10), 876-884.
27. Hettema, J. M., An, S. S., Neale, M. C., Bukszar, J., Van Der Oord, E. J., Kendler, K. S., et al. (2006). Association between glutamic acid decarboxylase genes and anxiety disorders, major depression, and neuroticism. Molecular Psychiatry, 11(8), 752-762.
28. Hou, C., Jia, F., Liu, Y., & Li, L. (2006). CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. Brain Research, 1095(1), 154-158.
29. Isogawa, K., Nagayama, H., Tsutsumi, T., Kiyota, A., Akiyoshi, J., & Hieda, K. (2005). Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropinreleasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder. Journal of Psychiatric Research, 39(5), 467-473.
30. Keller, M.,Montgomery, S., Ball,W.,Morrison, M., Snavely, D., Liu, G., et al. (2006). Lack of efficacy of the substance P (neurokinin 1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biological Psychiatry, 59(3), 216-233.
31. Kennedy, S. E., Koeppe, R. A., Young, E. A., & Zubieta, J. K. (2006). Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Archives of General Psychiatry, 63(11), 1199-1208.
32. Kim, H., Lim, S. W., Kim, S., Kim, J. W., Chang, Y. H., Carroll, B. J., et al. (2006).Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA: The Journal of the American Medical Association, 296(13), 1603-1618.
33. Kornum, B. R., Weikop, P., Moller, A., Ronn, L. C., Knudsen, G. M., & Aznar, S. (2006). Serotonin depletion reuptake in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus. Brain Research, 262(8), 1073-1074.
34. Kunugi, H., Ida, I., Owaski, T., Kimura, M., Inoue, Y., Nakagawa, S., et al. (2006). Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: A multicenter study. Neuropsychopharmacology, 31(1), 212-220.
35. Kunzel, H. E., Zobel, A. W., Nickel, T., Ackl, N., Uhr, M., Sonntag, A., et al. (2003). Treatment of depression with the CRH-1-receptor antagonist R 121919: Endocrine changes and side effects. Journal of Psychiatric Research, 37(6), 525-533.
36. Lai, I. C., Hong, C. J., & Tasi, S. J. (2001). Association study of nicotinic-receptor variants and major depressive disorders. Journal of Affective Disorders, 66(1), 79-82.
37. Lemos, J. C., Pan, Y. Z.,Ma, X., Lamy, C., Akanowa, A. C., & Buch, S.G. (2006). Selective 5-HT receptor inhibition of glutaminergic and GABAergic synaptic activity in the rat dorsal and median raphe. The European Journal of Neuroscience, 24(12), 3415-3430.
38. Leonard, B. E. (2005). The HPA and immune axes in stress: The involvement of the serotonergic system. European Psychiatry, 20(Suppl. 3), S302-S306.
39. Lieb, K., Fiebich, B. L., Herpfer, I., Mantovani, M., Loffler, M., & Feuerstein, T. J. (2005). No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes. European Neuropsychopharmacology, 15(6), 641-646.
40. Lieb, K., Walden, J., Grunze, H., Fiebich, B. L., Berger, M., & Normann, C. (2004). Serum levels of substance P and response to antidepressant pharmacotherapy. Pharmacopsychiatry, 37(5), 238-239.
41. Liu, G. X., Cai, G. Q., Cai, Y. Q., Sheng, Z. J., Jiang, J., Mei, Z., et al. (2006). Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1. Neuropsychopharmacology, 32(7), 1531-1539.
42. Lu, X., Barr, A. M., Kinney, J. W., Sanna, P., Conti, B., Behrens, M. M., et al. (2005). A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proceedings of the National Academy of Sciences of the United States of America, 102(3), 874-879.
43. Mendlewicz, J., Oswald, P., Claes, S., Massat, I., Souery, D., Van Broeckhoven, C., et al. (2005). Patient-control association study of substance P-related genes in unipolar and bipolar affective disorders. The International Journal of Neuropsychopharmacology, 8(4), 505-513.
44. Merali, Z., Kent, P., Du, L., Hodinga, P., Palkovits, M., Faludi, G., et al. (2006). Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biological Psychiatry, 59(7), 594-602.
45. Meyer, J. H., McNeely, H. F., Sagrati, S., Boovariwala, A., Martin, K., Verhoeff, N. P., et al. (2006). Elevated putamen D(2) receptor binding potential inmajor depression with motor retardation: An [11C] raclopride positron emission tomography study. The American Journal of Psychiatry, 163(9), 1594-1602.
46. Meynen, G., Unmehopa, U. A., van Heerikhuize, J. J., Hofman, M. A., Swaab, D. F., & Hoogendijk, W. J. (2006). Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: A preliminary report. Biological Psychiatry, 60(8), 892-895.
47. Navines, R., Mart́in-Santos, R., Ǵomez-Gil, E., Mart́inez de Osaba, M. J., Imaz, M. L., & Gasto, L. (2007). Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT(1A) receptor agonist buspirone in patients with major depression and therapeutic response. Psychoneuroendocrinology, 32(3), 307-312.
48. Newberg, A., Amsterdam, J., & Shults, J. (2007). Dopamine transporter density may be associated with the depressed affect in healthy subjects. Nuclear Medicine Communications, 28(1), 3-6.
49. Nierenberg, A. A., Greist, J. H., Mallinckrodt, G. D., Prakash, A., Sambunaris, A., Topllefion, G. D., et al. (2007). Dulexetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: Onset of antidepressant action, noninferiority study. Current Medical Research and Opinion, 23(2), 401-416.
50. Nikisch, G., Agren, H., Eap, C. B., Czernik, A., Baumann, P., & Mathe, A. A. (2005a). Neuropeptide Y and corticotropinreleasing hormone in CSF mark response to antidepressive treatment with citalopram. The International Journal of Neuropsychopharmacology, 8(3), 403-410.
51. Nikisch, G., Mathe, A. A., Czernik, A., Thiele, J., Bohner, J., Eap, C. B., et al. (2005b). Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: Relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology, 181(4), 751-760.
52. Nowak, G., Partyka, A., Palucha, A., Szawczyk, B., Wieronska, J. M., Dybate, M., et al. (2006). Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. British Journal of Pharmacology, 149(5), 581-590.
53. Nutt, D. J., Baldwin, D. S., Clayton, A. H., Elgie, R., Lecrubier, Y., Montejo, A. L., et al. (2006). Consensus statement and research needs: The role of dopamine and norepinephrine in depression and antidepressant treatment. The Journal of Clinical Psychiatry, 67(6), 46-49.
54. Nutt, D. J., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., et al. (2007). The other face of depression, reduced positive effect: The role of catecholamines in causation and cure. Journal of Psychopharmacology, 21(5), 461-471.
55. Pae, L.U., Serretti, A., Mandelli, L.,De Ronchi, P., Pathar, A. A., Jun, T. Y., et al. (2007). Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenetics and Genomics, 17(1), 69-79.
56. Palucha, A. (2006). Are compounds acting at metabotropic glutamate receptors the answer to treating depression? Expert Opinion on Investigational Drugs, 15(12), 1545-1553.
57. Rosenzweig-Lipson, S., Sabb, A., Stack, G., Mitchell, P., Lucki, I., Malberg, J. E., et al. (2007). Antidepressant-like effects of the novel, selective, 5-HT(2C) receptor agonist WAY-16309 in rodents. Psychopharmacology, 192(2), 159-170.
58. Ruhe, H. G., Mason, N.S., & Schene, A.H. (2007). Mood is directly related to serotonin, norepinephrine and dopamine levels in humans: A meta-analysis of monoamine depletion studies. Molecular Psychiatry, 12(4), 331-359.
59. Sanacora, G., Kendell, S. F., Levin, Y., Simen, A. A., Tenton, L. R., Covic, V., et al. (2007). Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biological Psychiatry, 61(6), 822-825.
60. Śanchez, C., Brennum, L. T., St́orustovu, S., Kreilgard, M., & Mork, A. (2007). Depression and poor sleep: The effect of monoaminergic antidepressant in a pre-clinical model in rats. Pharmacology, Biochemistry, and Behavior, 86(3), 468-476.
61. Schüle, C., Baghai, T. C., Alajbegovic, L., Schwarz, M., Zwanzger, P., Eser, D., et al. (2005). The effect of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients. European Archives of Psychiatry and Clinical Neuroscience, 255(5), 334-340.
62. Schüle, C., Baghai, T. C., Eser, D., Zwanzger, P., Jordan, M., Buechs, R., et al. (2006). Time course of hypothalamic-pituitaryadrenocortical axis activity during treatment with reboxetine and mirtrazapine in depressed patients. Psychopharmacology (Berlin), 186(4), 601-611.
63. Sergeyev, V., Tetivsov, S., Mathe, A. A., Jiḿenez, P. A., Bartfai, T., Mortas, P., et al. (2005). Neuropeptide expression in rats exposed to chronic mild stresses. Psychopharmacology (Berlin), 178(2-3), 115-124.
64. Sinei, K. A., & Redfern, P. H. (1993). The effects of chronic clomipramine and mianserin on the activity of tryptophan hydroxylase in the rat brain. East African Medical Journal, 70(11), 721-724.
65. Skolnick, P., Krieter, P., Tizzano, J., Basile, A., Popik, P., Czolor, P., et al. (2006). Preclinical and clinical pharmacology of DOV 216 303, a "triple" reuptake inhibitor. CNS Drug Reviews, 12(2), 123-134.
66. Stone, E. A., Quartermain, D., Lin, Y., & Lehmann, M. L. (2006). Central alpha(1)-adrenergic system in behavioral activity and depression. Biochemical Pharmacology, 73(8), 1063-1075.
67. Szuba, M. P., Amsterdam, J. D., Fernando, A. T., 3rd, Gary, K. A., Whybrow, P. C., & Winokuv, A. (2005). Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. Journal of Clinical Psychopharmacology, 25(4), 325-330.
68. Taner, E., Demin, E. Y., & Cosar, B. (2006). Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: A single-blind, randomized clinical trial. Advances in Therapy, 23(6), 974-987.
69. Thase, M. E., Clayton, A. H., Haight, B. R., Thompson, H. H., Modell, J. G., & Johnston, J. A. (2006). A double-blind comparison between bupropion XL and venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability. Journal of Clinical Psychopharmacology, 26(5), 482-488.
70. Thompson, S. E., Ayman, G., Woodhall, G. L., & Jones, R. S. (2007). Depression of glutamate and GABA release by presynaptic GABA(B) receptors in the entorhinal cortex in normal and chronically epileptic rats. Neurosignals, 15(4), 202-215.
71. Tordera, R. M., Tottendell, S., Wojcik, S. M., Brose, N., Elizade, N., Lasheras, B., et al. (2007). Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter gene 1 (VGLLT 1). The European Journal of Neuroscience, 25(1), 281-290.
72. Wang, J. C., Hinrichs, A. L., Stock, H., Budde, J., Allen, R., Bertelsen, S., et al. (2004). Evidence of common and specific genetic effects: Association of muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Human Molecular Genetics, 13(17), 1903-1911.
73. Werner, F. M. (2004). Theoretical reflections about the reciprocal influence of neurotransmitters upon each other. Klinicḱa Neurologie, 35, 125-222.
74. Werner, F. M. (2006). Schizophrenia: From the genetic localization to the cellular mechanism. Klinicḱa Neurologie, 37, 19-107.
75. Werner, F.M. (2007). Classical neurotransmitters involved in Parkinson's disease. Journal of Neural Transmission, 114, I-XXXI.
76. Werner, F. M., & Coveñas, R. (2005). Neuropeptides involved in schizophrenia. Current Topics in Neurochemistry, 4, 35-49.
77. Werner, F. M., & Covenas, R. (2007). Neuropeptides and classical neurotransmitters involved in Parkinson and Alzheimer diseases. In R. Covenas, A. Mangas, and J. A. Narv́aez (eds.), Focus on Neuropeptide Research. Trivandrum: Transworld Research Network, 299-339.
78. Wheatland, R. (2005). Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic- pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. Medical Hypotheses, 65(2), 287-295.
79. Zhou, J. (2004). Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future, 29(12), 1235-1244.